13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • DASL-HiCaP

    Acronym: 

    DASL-HiCaP

    ACTRN/NCT /ethics: 

    NCT04136353

    Scientific title: 

    Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)

    Summary of trial and patient characteristics

    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase III Tumour Stream Prostate
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Male Anticipated Start Date 2020-01-31
    Molecular Target Anticipated End Date 2028-07-31
    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Male
    Molecular Target
    Tumour Stream Prostate
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2020-01-31
    Anticipated End Date 2028-07-31

    Trial Summary

    Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation and definitive or salvage radiation in very high risk, clinically localised prostate cancer

    Lay Summary

    Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Sue Yeend syeend@adelaidecancercentre.com.au 08 8292 2240 Dr Francis Parnis Not Yet Recruiting